APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Plant Derivative Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Plant Derivative Drug Market Outlook and Growth Opportunities 2026

Report ID 17402630042 January 2026190 pages

Choose your research edition.

Industry ResearchPlant Derivative Drug Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Plant Derivative Drug Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Plant Derivative Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Plant Derivative Drug Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Plant Derivative Drug Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Plant Derivative Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Plant Derivative Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Plant Derivative Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Plant Derivative Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Plant Derivative Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Plant Derivative Drug market include Yunnan Baiyao, Weleda, Tsumura, Tong Ren Tang, Tasly Holding Group, Taiji, Schwabe, Kwangdong and Jumpcan Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Plant Derivative Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Plant Derivative Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Plant Derivative Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Plant Derivative Drug market.

Plant Derivative Drug Segment by Company

Yunnan Baiyao

Weleda

Tsumura

Tong Ren Tang

Tasly Holding Group

Taiji

Schwabe

Kwangdong

Jumpcan Pharmaceutical

Huarun 999

GW Pharmaceuticals

Guangzhou Baiyunshan Pharmaceutical

China TCM

Buchang Pharmaceuticals

Bionorica Se

Plant Derivative Drug Segment by Type

Prescription Drug

OTC

Plant Derivative Drug Segment by Application

Tumor

Cardiovascular

Respiratory System

Other

Plant Derivative Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Plant Derivative Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Plant Derivative Drug key companies, revenue, market share, and recent developments.

3. To split the Plant Derivative Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Plant Derivative Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Plant Derivative Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Plant Derivative Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plant Derivative Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Plant Derivative Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plant Derivative Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Plant Derivative Drug industry.

Chapter 3: Detailed analysis of Plant Derivative Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Plant Derivative Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Plant Derivative Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Plant Derivative Drug Industry Trends Table 2. Plant Derivative Drug Industry Drivers Table 3. Plant Derivative Drug Industry Opportunities and Challenges Table 4. Plant Derivative Drug Industry Restraints Table 5. Global Plant Derivative Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Plant Derivative Drug Revenue Share by Company (2021-2026) Table 7. Global Plant Derivative Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Plant Derivative Drug Key Company Manufacturing Base & Headquarters Table 9. Global Plant Derivative Drug Company, Product Type & Application Table 10. Global Plant Derivative Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Plant Derivative Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Prescription Drug Table 15. Significant Companies of OTC Table 16. Global Plant Derivative Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Plant Derivative Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Plant Derivative Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Plant Derivative Drug Sales Value Share by Type (2021-2026) Table 20. Global Plant Derivative Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Tumor Table 22. Significant Companies of Cardiovascular Table 23. Significant Companies of Respiratory System Table 24. Significant Companies of Other Table 25. Global Plant Derivative Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Plant Derivative Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Plant Derivative Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Plant Derivative Drug Sales Value Share by Application (2021-2026) Table 29. Global Plant Derivative Drug Sales Value Share by Application (2027-2032) Table 30. Global Plant Derivative Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Plant Derivative Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Plant Derivative Drug Sales Value Share by Region (2021-2026) Table 33. Global Plant Derivative Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Plant Derivative Drug Sales Value Share by Region (2027-2032) Table 35. Global Plant Derivative Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Plant Derivative Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Plant Derivative Drug Sales Value Market Share by Country (2021-2026) Table 38. Global Plant Derivative Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Plant Derivative Drug Sales Value Market Share by Country (2027-2032) Table 40. Yunnan Baiyao Company Information Table 41. Yunnan Baiyao Business Overview Table 42. Yunnan Baiyao Plant Derivative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Yunnan Baiyao Plant Derivative Drug Product Portfolio Table 44. Yunnan Baiyao Recent Development Table 45. Weleda Company Information Table 46. Weleda Business Overview Table 47. Weleda Plant Derivative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Weleda Plant Derivative Drug Product Portfolio Table 49. Weleda Recent Development Table 50. Tsumura Company Information Table 51. Tsumura Business Overview Table 52. Tsumura Plant Derivative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Tsumura Plant Derivative Drug Product Portfolio Table 54. Tsumura Recent Development Table 55. Tong Ren Tang Company Information Table 56. Tong Ren Tang Business Overview Table 57. Tong Ren Tang Plant Derivative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Tong Ren Tang Plant Derivative Drug Product Portfolio Table 59. Tong Ren Tang Recent Development Table 60. Tasly Holding Group Company Information Table 61. Tasly Holding Group Business Overview Table 62. Tasly Holding Group Plant Derivative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Tasly Holding Group Plant Derivative Drug Product Portfolio Table 64. Tasly Holding Group Recent Development Table 65. Taiji Company Information Table 66. Taiji Business Overview Table 67. Taiji Plant Derivative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Taiji Plant Derivative Drug Product Portfolio Table 69. Taiji Recent Development Table 70. Schwabe Company Information Table 71. Schwabe Business Overview Table 72. Schwabe Plant Derivative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Schwabe Plant Derivative Drug Product Portfolio Table 74. Schwabe Recent Development Table 75. Kwangdong Company Information Table 76. Kwangdong Business Overview Table 77. Kwangdong Plant Derivative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Kwangdong Plant Derivative Drug Product Portfolio Table 79. Kwangdong Recent Development Table 80. Jumpcan Pharmaceutical Company Information Table 81. Jumpcan Pharmaceutical Business Overview Table 82. Jumpcan Pharmaceutical Plant Derivative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Jumpcan Pharmaceutical Plant Derivative Drug Product Portfolio Table 84. Jumpcan Pharmaceutical Recent Development Table 85. Huarun 999 Company Information Table 86. Huarun 999 Business Overview Table 87. Huarun 999 Plant Derivative Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Huarun 999 Plant Derivative Drug Product Portfolio Table 89. Huarun 999 Recent Development Table 90. GW Pharmaceuticals Company Information Table 91. GW Pharmaceuticals Business Overview Table 92. GW Pharmaceuticals Plant Derivative Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. GW Pharmaceuticals Plant Derivative Drug Product Portfolio Table 94. GW Pharmaceuticals Recent Development Table 95. Guangzhou Baiyunshan Pharmaceutical Company Information Table 96. Guangzhou Baiyunshan Pharmaceutical Business Overview Table 97. Guangzhou Baiyunshan Pharmaceutical Plant Derivative Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Guangzhou Baiyunshan Pharmaceutical Plant Derivative Drug Product Portfolio Table 99. Guangzhou Baiyunshan Pharmaceutical Recent Development Table 100. China TCM Company Information Table 101. China TCM Business Overview Table 102. China TCM Plant Derivative Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. China TCM Plant Derivative Drug Product Portfolio Table 104. China TCM Recent Development Table 105. Buchang Pharmaceuticals Company Information Table 106. Buchang Pharmaceuticals Business Overview Table 107. Buchang Pharmaceuticals Plant Derivative Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Buchang Pharmaceuticals Plant Derivative Drug Product Portfolio Table 109. Buchang Pharmaceuticals Recent Development Table 110. Bionorica Se Company Information Table 111. Bionorica Se Business Overview Table 112. Bionorica Se Plant Derivative Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Bionorica Se Plant Derivative Drug Product Portfolio Table 114. Bionorica Se Recent Development Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Plant Derivative Drug Product Image Figure 2. Global Plant Derivative Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Plant Derivative Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Plant Derivative Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Prescription Drug Image Figure 8. OTC Image Figure 9. Global Plant Derivative Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Plant Derivative Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Plant Derivative Drug Sales Value Share by Type (2021-2032) Figure 12. Tumor Image Figure 13. Cardiovascular Image Figure 14. Respiratory System Image Figure 15. Other Image Figure 16. Global Plant Derivative Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Plant Derivative Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Plant Derivative Drug Sales Value Share by Application (2021-2032) Figure 19. Global Plant Derivative Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Plant Derivative Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Plant Derivative Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America Plant Derivative Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Plant Derivative Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Plant Derivative Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Plant Derivative Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Plant Derivative Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Plant Derivative Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America Plant Derivative Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Plant Derivative Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Plant Derivative Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Plant Derivative Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Prescription Drug
  • OTC
Applications
  • Tumor
  • Cardiovascular
  • Respiratory System
  • Other
Companies covered
  • Yunnan Baiyao
  • Weleda
  • Tsumura
  • Tong Ren Tang
  • Tasly Holding Group
  • Taiji
  • Schwabe
  • Kwangdong
  • Jumpcan Pharmaceutical
  • Huarun 999
  • GW Pharmaceuticals
  • Guangzhou Baiyunshan Pharmaceutical
  • China TCM
  • Buchang Pharmaceuticals
  • Bionorica Se

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Plant Derivative Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Plant Derivative Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Plant Derivative Drug Market Dynamics
  1. 2.1 Plant Derivative Drug Industry Trends
  2. 2.2 Plant Derivative Drug Industry Drivers
  3. 2.3 Plant Derivative Drug Industry Opportunities and Challenges
  4. 2.4 Plant Derivative Drug Industry Restraints
3 Plant Derivative Drug Market by Company
  1. 3.1 Global Plant Derivative Drug Company Revenue Ranking in 2025
  2. 3.2 Global Plant Derivative Drug Revenue by Company (2021-2026)
  3. 3.3 Global Plant Derivative Drug Company Ranking (2024-2026)
  4. 3.4 Global Plant Derivative Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Plant Derivative Drug Company Product Type and Application
  6. 3.6 Global Plant Derivative Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Plant Derivative Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Plant Derivative Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Plant Derivative Drug Market by Type
  1. 4.1 Plant Derivative Drug Type Introduction
  2. 4.1.1 Prescription Drug
  3. 4.1.2 OTC
  4. 4.2 Global Plant Derivative Drug Sales Value by Type
  5. 4.2.1 Global Plant Derivative Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Plant Derivative Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global Plant Derivative Drug Sales Value Share by Type (2021-2032)
5 Plant Derivative Drug Market by Application
  1. 5.1 Plant Derivative Drug Application Introduction
  2. 5.1.1 Tumor
  3. 5.1.2 Cardiovascular
  4. 5.1.3 Respiratory System
  5. 5.1.4 Other
  6. 5.2 Global Plant Derivative Drug Sales Value by Application
  7. 5.2.1 Global Plant Derivative Drug Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Plant Derivative Drug Sales Value by Application (2021-2032)
  9. 5.2.3 Global Plant Derivative Drug Sales Value Share by Application (2021-2032)
6 Plant Derivative Drug Regional Value Analysis
  1. 6.1 Global Plant Derivative Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Plant Derivative Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Plant Derivative Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Plant Derivative Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Plant Derivative Drug Sales Value (2021-2032)
  7. 6.3.2 North America Plant Derivative Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Plant Derivative Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Plant Derivative Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Plant Derivative Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Plant Derivative Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Plant Derivative Drug Sales Value (2021-2032)
  16. 6.6.2 South America Plant Derivative Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Plant Derivative Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Plant Derivative Drug Sales Value Share by Country, 2025 VS 2032
7 Plant Derivative Drug Country-level Value Analysis
  1. 7.1 Global Plant Derivative Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Plant Derivative Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Plant Derivative Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Plant Derivative Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Plant Derivative Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Plant Derivative Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Plant Derivative Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yunnan Baiyao
  2. 8.1.1 Yunnan Baiyao Company Information
  3. 8.1.2 Yunnan Baiyao Business Overview
  4. 8.1.3 Yunnan Baiyao Plant Derivative Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Yunnan Baiyao Plant Derivative Drug Product Portfolio
  6. 8.1.5 Yunnan Baiyao Recent Developments
  7. 8.2 Weleda
  8. 8.2.1 Weleda Company Information
  9. 8.2.2 Weleda Business Overview
  10. 8.2.3 Weleda Plant Derivative Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Weleda Plant Derivative Drug Product Portfolio
  12. 8.2.5 Weleda Recent Developments
  13. 8.3 Tsumura
  14. 8.3.1 Tsumura Company Information
  15. 8.3.2 Tsumura Business Overview
  16. 8.3.3 Tsumura Plant Derivative Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Tsumura Plant Derivative Drug Product Portfolio
  18. 8.3.5 Tsumura Recent Developments
  19. 8.4 Tong Ren Tang
  20. 8.4.1 Tong Ren Tang Company Information
  21. 8.4.2 Tong Ren Tang Business Overview
  22. 8.4.3 Tong Ren Tang Plant Derivative Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Tong Ren Tang Plant Derivative Drug Product Portfolio
  24. 8.4.5 Tong Ren Tang Recent Developments
  25. 8.5 Tasly Holding Group
  26. 8.5.1 Tasly Holding Group Company Information
  27. 8.5.2 Tasly Holding Group Business Overview
  28. 8.5.3 Tasly Holding Group Plant Derivative Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Tasly Holding Group Plant Derivative Drug Product Portfolio
  30. 8.5.5 Tasly Holding Group Recent Developments
  31. 8.6 Taiji
  32. 8.6.1 Taiji Company Information
  33. 8.6.2 Taiji Business Overview
  34. 8.6.3 Taiji Plant Derivative Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Taiji Plant Derivative Drug Product Portfolio
  36. 8.6.5 Taiji Recent Developments
  37. 8.7 Schwabe
  38. 8.7.1 Schwabe Company Information
  39. 8.7.2 Schwabe Business Overview
  40. 8.7.3 Schwabe Plant Derivative Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Schwabe Plant Derivative Drug Product Portfolio
  42. 8.7.5 Schwabe Recent Developments
  43. 8.8 Kwangdong
  44. 8.8.1 Kwangdong Company Information
  45. 8.8.2 Kwangdong Business Overview
  46. 8.8.3 Kwangdong Plant Derivative Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Kwangdong Plant Derivative Drug Product Portfolio
  48. 8.8.5 Kwangdong Recent Developments
  49. 8.9 Jumpcan Pharmaceutical
  50. 8.9.1 Jumpcan Pharmaceutical Company Information
  51. 8.9.2 Jumpcan Pharmaceutical Business Overview
  52. 8.9.3 Jumpcan Pharmaceutical Plant Derivative Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jumpcan Pharmaceutical Plant Derivative Drug Product Portfolio
  54. 8.9.5 Jumpcan Pharmaceutical Recent Developments
  55. 8.10 Huarun 999
  56. 8.10.1 Huarun 999 Company Information
  57. 8.10.2 Huarun 999 Business Overview
  58. 8.10.3 Huarun 999 Plant Derivative Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Huarun 999 Plant Derivative Drug Product Portfolio
  60. 8.10.5 Huarun 999 Recent Developments
  61. 8.11 GW Pharmaceuticals
  62. 8.11.1 GW Pharmaceuticals Company Information
  63. 8.11.2 GW Pharmaceuticals Business Overview
  64. 8.11.3 GW Pharmaceuticals Plant Derivative Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GW Pharmaceuticals Plant Derivative Drug Product Portfolio
  66. 8.11.5 GW Pharmaceuticals Recent Developments
  67. 8.12 Guangzhou Baiyunshan Pharmaceutical
  68. 8.12.1 Guangzhou Baiyunshan Pharmaceutical Company Information
  69. 8.12.2 Guangzhou Baiyunshan Pharmaceutical Business Overview
  70. 8.12.3 Guangzhou Baiyunshan Pharmaceutical Plant Derivative Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Guangzhou Baiyunshan Pharmaceutical Plant Derivative Drug Product Portfolio
  72. 8.12.5 Guangzhou Baiyunshan Pharmaceutical Recent Developments
  73. 8.13 China TCM
  74. 8.13.1 China TCM Company Information
  75. 8.13.2 China TCM Business Overview
  76. 8.13.3 China TCM Plant Derivative Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 China TCM Plant Derivative Drug Product Portfolio
  78. 8.13.5 China TCM Recent Developments
  79. 8.14 Buchang Pharmaceuticals
  80. 8.14.1 Buchang Pharmaceuticals Company Information
  81. 8.14.2 Buchang Pharmaceuticals Business Overview
  82. 8.14.3 Buchang Pharmaceuticals Plant Derivative Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Buchang Pharmaceuticals Plant Derivative Drug Product Portfolio
  84. 8.14.5 Buchang Pharmaceuticals Recent Developments
  85. 8.15 Bionorica Se
  86. 8.15.1 Bionorica Se Company Information
  87. 8.15.2 Bionorica Se Business Overview
  88. 8.15.3 Bionorica Se Plant Derivative Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Bionorica Se Plant Derivative Drug Product Portfolio
  90. 8.15.5 Bionorica Se Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst